Patents by Inventor David Modrak

David Modrak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPHINGOMYELIN THERAPY OF AUTOIMMUNE DISEASE
    Publication number: 20080096845
    Abstract: Autoimmune disease therapy in a patient treated with apoptosis-inducing agents is enhanced by co-administration of sphingomyelin. The combination most likely enhances an autoimmune disease cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. In alternative embodiments, sphingomyelin may be administered alone, in combination with corticosteroids, and/or in combination with a apoptosis-inducing agent.
    Type: Application
    Filed: September 18, 2007
    Publication date: April 24, 2008
    Applicant: CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY
    Inventors: David Modrak, David Goldenberg
  • Sphingomyelin enhancement of tumor therapy
    Patent number: 7288534
    Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: October 30, 2007
    Assignee: Center for Molecular Medicine and Immunology
    Inventors: David Modrak, David M. Goldenberg
  • Sphingomyelin enhancement of tumor therapy
    Publication number: 20030228257
    Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
    Type: Application
    Filed: February 14, 2003
    Publication date: December 11, 2003
    Applicant: Center for Molecular Medicine and Immunology
    Inventor: David Modrak
  • Sphingomyelin enhancement of tumor therapy
    Patent number: 6541462
    Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: April 1, 2003
    Assignee: Center for Molecular Medicine and Immunology
    Inventor: David Modrak